Join to view full profile
One Long Wharf, 2nd FloorYale New Haven Children's Hospital Pediatric Specialty CenterNew Haven, CT 06511
Dr. Carpenter is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Boston Children’s Hospital/Boston Medical CenterFellowship, Pediatric Endocrinology, 1980 - 1983
University of Alabama Hospital (Birmingham)Residency, Pediatrics, 1977 - 1980
University of Alabama School of MedicineClass of 1977
Certifications & Licensure
CT State Medical License 1986 - 2027
AL State Medical License 1978 - 1978
American Board of Pediatrics Pediatrics- American Board of Pediatrics Pediatric Endocrinology
Awards, Honors, & Recognition
- Top Doctors: New York Metro Area Castle Connolly, 2004-2014
- New York Magazine: Top Doctors Castle Connolly, 2005-2007, 2014
Clinical Trials
Publications & Presentations
PubMed
- Somatic Mosaicism Modulating Clinical Severity in COL2A1-Related Skeletal Dysplasia: A Case of Profound Skeletal Asymmetry.Rukiye Sena Turk Yilmaz, Lisa Cruz, Cemre Robinson, Allen E Bale, Thomas O Carpenter
Calcified Tissue International. 2026-09-18 - Real-world outcomes in patients with tumor-induced osteomalacia treated vs not treated with burosumab.María Belén Zanchetta, Kathryn M Dahir, Erik A Imel, Thomas O Carpenter, Kerry Sandilands
Journal of the Endocrine Society. 2026-09-01 - 2 citationsReal-world effectiveness of burosumab across age groups: X-linked hypophosphatemia (XLH) Disease Monitoring Program.Leanne M Ward, Thomas O Carpenter, Hamilton Cassinelli, Pablo Florenzano, Erik A Imel
The Journal of Clinical Endocrinology and Metabolism. 2026-08-13
Journal Articles
- A Randomized, Double‐Blind, Placebo‐Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti‐FGF23 Antibody, in Adults with X‐Linked Hypophosphatemia: W...Thomas Weber, Mary D Ruppe, Anthony A Portale, Erik A Imel, Thomas O Carpenter, Karl L Insogna, Farzana Perwad, Pisit Pitukcheewanont, Journal of Bone and Mineral Research
Press Mentions
Burosumab May Benefit Children with X-linked HypophosphatemiaMay 28th, 2018
Grant Support
- Physiology CoreNational Institute Of Arthritis And Musculoskeletal And Skin Diseases2007–2012
- Classical And Non-Classical Responses To Vitamin D In Children: The Role Of DBP GEunice Kennedy Shriver National Institute Of Child Health &Human Development2009–2010
- P1: The Role Of Parathyroid Hormone In The Pathogenesis Of Skeletal Disease In X-National Institute Of Arthritis And Musculoskeletal And Skin Diseases2006–2010
- Niams: CortNational Institute Of Arthritis And Musculoskeletal And Skin Diseases2006–2010
- Administrative CoreNational Institute Of Arthritis And Musculoskeletal And Skin Diseases2007
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: